Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych CASC / OSCEPsychopharmacology — anxiolytics and hypnotics

Psych CASC / OSCE · Psychopharmacology — anxiolytics and hypnotics

Negotiating short-term hypnotic use and a deprescribing plan (CASC)

CASC-style station: explain GABA-A risks in older adults, refuse automatic Z-drug swap as a safety solution, offer CBT-I/sleep strategies and optional modest melatonin, and co-design a gradual taper with falls safety-netting.

communication
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 71-year-old retired teacher has taken temazepam 20 mg nocte for 4 years after bereavement insomnia. She fell twice last month. Her daughter (in the room) found online that 'Z-drugs are safer' and asks to switch to zolpidem forever. The patient fears she will 'never sleep again' without tablets and becomes tearful when deprescribing is mentioned.

Station instructions (candidate)

You have 7 minutes. Explain why long-term temazepam is no longer the safest plan after falls, address the Z-drug myth, and negotiate a gradual deprescribing plan with sleep supports. Include the daughter without talking over the patient. Avoid scaremongering and avoid false safety guarantees.[1][2][4]

Marking domains

Empathy and agenda; accurate plain-language mechanism (calming brain pathways that become less helpful and more hazardous over time); falls and cognition risk grounded in older-adult evidence; clear statement that Z-drugs still act on related GABA systems and are not a free pass; shared taper plan (pace, follow-up, what if rebound insomnia); CBT-I/sleep hygiene and optional modest melatonin; safety-net for severe withdrawal symptoms (rare but serious if abrupt stop).[1][5][6][7][8]

Model communication map

  1. Open: thank them; name the falls and sleep worry as twin goals — sleep without another broken hip.[1]
  2. Validate: long-term tablets often started for real grief insomnia; body adapts so stopping suddenly can feel awful — we will not abandon her.[5]
  3. Risk truth: in older adults, sedative-hypnotics give modest sleep gain with meaningful falls/cognition risk; guidelines list them as often inappropriate long-term.[1][2]
  4. Z-drug myth: switching to zolpidem is not a safety solution — related brain target, residual impairment and dependence potential still matter.[7][2]
  5. Plan: slow dose reductions (explain 10–25% style scaffolding in plain language), more time between steps if needed, written schedule, GP/psychiatry reviews.[4][5]
  6. Sleep supports: stimulus control, consistent rise time, CBT-I referral; optional melatonin with honest modest-expectation framing.[8][6]
  7. Education tool: patient-facing education can help people choose deprescribing (EMPOWER message) — offer leaflet/summary.[3]
  8. Safety-net: do not stop overnight; call if severe shaking, confusion, or seizure — reinstate cover then re-taper more slowly.[5]
  9. Close: questions; next appointment date; daughter as support not enforcer.

Common fails

  • Agreeing to lifelong zolpidem as "safer benzodiazepine alternative."[7]
  • Ordering abrupt cessation after four years continuous use.[5]
  • Ignoring falls history while only discussing addiction stigma.[1]
  • Over-promising perfect sleep on melatonin alone.[6]
  • Speaking only to the daughter and sidelining the patient.

References

  1. [1]Glass J, Lanctôt KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits BMJ, 2005.PMID 16284208
  2. [2]By the 2023 American Geriatrics Society Beers Criteria Update Expert Panel American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults J Am Geriatr Soc, 2023.PMID 37139824
  3. [3]Tannenbaum C, Martin P, Tamblyn R, et al. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial JAMA Intern Med, 2014.PMID 24733354
  4. [4]Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline Can Fam Physician, 2018.PMID 29760253
  5. [5]Soyka M Treatment of Benzodiazepine Dependence N Engl J Med, 2017.PMID 28328330
  6. [6]Ferracioli-Oda E, Qawasmi A, Bloch MH Meta-analysis: melatonin for the treatment of primary sleep disorders PLoS One, 2013.PMID 23691095
  7. [7]Gunja N The clinical and forensic toxicology of Z-drugs J Med Toxicol, 2013.PMID 23404347
  8. [8]Wilson S, Anderson K, Baldwin D, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update J Psychopharmacol, 2019.PMID 31271339